Bharat Biotech, GSK join hands to develop vaccine for severe diarrhoea
Bharat Biotech
on Thursday said it has partnered with
GSK plc
for the development of a vaccine for Shigellosis, a severe form of
bacterial diarrhoea
.
The altSonflex1-2-3 vaccine candidate, developed by
GSK
and now advancing through a strategic collaboration with Bharat Biotech, represents one of the most advanced Shigella vaccine candidates globally, the company said in a statement.
With no licensed Shigella vaccine currently available and rising
antimicrobial resistance
, this candidate stands out for its broad serotype coverage, innovative
Generalized Modules for Membrane Antigens
(GMMA)-based platform, and robust early clinical results, it added.
"With no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries," Bharat Biotech Executive Chairman Krishna Ella said.
As part of this agreement, Bharat Biotech will lead the further development of altSonflex1-2-3, including Phase 3
clinical trials
, regulatory advancement, and large-scale manufacturing.
Live Events
GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the Access and Delivery Plans and commercialisation strategy.
"This agreement allows us to combine our strengths in science, research, and technology with Bharat Biotech's capacity to develop and deliver vaccines at scale, potentially preventing illness and saving lives around the world," GSK Chief Global Health Officer Thomas Breuer said.
Economic Times WhatsApp channel
)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
4 hours ago
- Hans India
India Records Over 7,000 Active COVID-19 Cases As Fresh Wave Continues In 2025
India's COVID-19 situation shows continued escalation as active cases reached 7,154 on Thursday morning, according to official data from the Ministry of Health and Family Welfare. The country recorded three additional COVID-related fatalities since Thursday, with two deaths in Maharashtra and one in Madhya Pradesh, bringing the total death count for 2025 to 77. Despite the rising infections, there has been encouraging progress in recoveries, with over 8,000 individuals successfully recovering from the infection throughout the current year. Kerala maintains its position as the most affected state in the current wave, reporting 2,223 active cases on Thursday morning. The southern state continues to account for the largest share of India's COVID-19 burden in 2025. Other states experiencing significant case loads include Gujarat, West Bengal, Delhi, and Maharashtra, according to the Centre's COVID-19 monitoring dashboard. While most states have registered slight increases in active cases, the distribution remains uneven across different regions of the country. Health experts attribute the recent surge to emerging Omicron sub-variants, specifically JN.1, NB.1.8.1, LF.7, and XFC strains. These variants demonstrate enhanced transmissibility compared to previous iterations but generally present with milder symptoms in infected individuals. The World Health Organization currently categorizes these strains as "Variants Under Monitoring," indicating they require careful observation but do not yet warrant classification as variants of concern. This designation reflects a cautious approach while acknowledging their increased spread potential. Medical authorities note that SARS-CoV-2, the virus responsible for COVID-19, has evolved from an unpredictable emergency threat to a more predictable endemic pathogen. The virus now follows recurring seasonal patterns similar to influenza, representing a significant shift in how health systems approach COVID-19 management. This transition suggests that while the virus remains present and active, its behavior has become more predictable, allowing for better preparation and response strategies. Healthcare systems are adapting their protocols to manage COVID-19 as part of routine respiratory illness surveillance rather than emergency pandemic response. The current data reflects ongoing vigilance by health authorities as they monitor transmission patterns and adapt public health measures accordingly.
The Hindu
4 hours ago
- The Hindu
Heart repair without surgery: The TEER procedure
Mitral Valve Leakage, also known as mitral regurgitation, is a symptomatic, cardiovascular condition wherein the mitral valve does not close tightly. This causes blood to flow backwards into the left atrium when the left ventricle contracts and onwards in towards the lungs causing severe blood pressure and symptoms. This is a serious heart condition usually observed in patients who have experienced heart attacks and have a dilated heart but can also occur in patients who are elderly and have diseased mitral valve which do not close properly. Reportedly more than 70% of the population on conventional medical treatment may die in case they are not offered treatments such as valve replacement, mitral annular surgery or TEER procedure. Mitral Valve Leakage: The Mitral Valve is a unidirectional valve located between the left atrium and the left ventricle, and it facilitates the flow of purified / oxygen rich blood from the lungs to the body. In a healthy heart, the mitral valve opens and closes tightly with each heartbeat preventing the blood flowing in reverse direction towards the lungs. When the mitral valve does not close tightly, the blood flows back into the left atrium, and the heart compensates for the blood leakage by pumping harder, masking the issue in the early years. As the severity of blood leakage increases with years within a few years it leads to compromised heart conditions which is irreversible and eventually fatal. Cause: The common observed causes for Mitral Valve Leakage are Degenerative Mitral Valve disease caused due to progressing age, atrial fibrillation, Rheumatic fever from untreated gum or throat infection, Heart attacks that cause damage to valve structures, Infective endocarditis, also known as Valve infection, and Congenital valve defects that arise due to birth defects. Symptoms: The early symptoms of the disease are usually observed at the age of 60 years and above. Shortness of breath Palpitations Swollen feet or ankles Heart murmur Light headedness or fatigue Chest discomfort, or weakness Fainting Detection: Mitral Valve defect can be diagnosed early through: Echocardiogram, a simple ultrasound of the heart Fetal Echocardiogram to detect valve defects during pregnancy or before birth, Electrocardiogram to detect Atrial fibrillation, and X-ray to check for heart enlargement. Early detection of the disease allows surgeons to manage the symptoms with medication and to avoid heart failure or atrial fibrillation. Treatment: For managing mild symptoms, surgeons usually prescribe medicines such as Diuretics to reduce fluid build-up, and Beta-Blockers and ACE inhibitors to improve heart function. Other newer medications include ARNI, SGLT-2 inhibitors which also improve heart function. In some patients where the pumping capacity of the heart is sufficient (>30%) the surgery may be considered. In majority of these patient the pumping capacity is severely compromised (<30%) and they are usually on medication and may be recommended TEER procedure based on its suitability. Transcatheter Edge-to-Edge Repair (TEER): The TEER procedure is highly recommended for patients who are considered high surgical risk due to pre-existing issues like hypertension, diabetes, obesity, advanced age, physical frailty, enlarged or weak heart, and patients with kidney, lung and liver problems. TEER is a minimally invasive procedure that is performed in a CATH Lab under general anaesthesia. During the procedure, a catheter is inserted through a incision near the groin, usually into the femoral vein, and guided to the mitral valve using real-time 3D Transoesophageal Echocardiography (TEE) and Fluoroscopy (X Ray imaging). A small clip is then attached to the Mitral valve leaflets to help them close tightly and reduce the backflow of blood (regurgitation) into the left atrium. The TEER procedure is usually completed within 3 hours. Benefits of the TEER procedure: Minimally invasive procedure that negates the need for open heart surgery Recommended for high-risk surgical patients with comorbidities Limited hospital stay of 3 to 5 days Reduced repeat heart failure hospitalisation Improves quality of life Lower post-surgical complications and faster recovery period Allows for future intervention, if required Post-surgery Hospitalisation and Recovery: Post the TEER procedure, the patient is kept under observation in an ICU for 24 hours to monitor heart rhythm, valve function, blood pressure, kidney function, symptoms of bleeding, arrhythmias or for any other valve-related complications. Patients are often discharged within 3 to 5 days of the procedure if they are well. Under medical guidance, patients usually resume daily activities like walking and non-strenuous work within a short period post the procedure. Post 6 weeks of the TEER procedure, patients have been observed to resume regular activities under medical supervision. Doctors may prescribe blood thinners or antiplatelets, with continuation of blood pressure or heart failure medication. Planned medical follow-ups are recommended to monitor valve function. Disclaimer: The views/suggestions/opinions expressed in the article are the sole responsibility of the brand concerned this should not be considered a substitute for medical advice. Please consult your treating physician for more details. 'This article is part of sponsored content programme.'
Time of India
15 hours ago
- Time of India
Nothing Phone (3) will be company's first-ever flagship to be manufactured in India
Nothing has confirmed that its upcoming flagship smartphone, the Phone (3), will be manufactured in India . The Phone (3) will be the company's first-ever flagship phone to be produced at Nothing's existing manufacturing facility in Chennai. This facility currently employs over 500 people, with 95% of the workforce being women. This decision is part of the London-based phone maker's strategy to boost its presence in the Indian market. The company wants to use India's position as a developing hub for manufacturing and technological innovation. This move also signifies a stronger focus on local production as Nothing expands its manufacturing capabilities in the producing key products locally, Nothing intends to enhance efficiency, reduce lead times, and respond more quickly to market demand. What Nothing said about making Phone (3) in India Commenting on the development, Akis Evangelidis , co-founder and India President of Nothing, said, 'India has been an important market for us ever since the very beginning of Nothing. Every one of our smartphones has been manufactured here — and Phone (3) proudly joins that list. As we accelerate our growth here, we're doubling down on our investment in local manufacturing , talent, and innovation — fully aligned with the Make in India vision. Phone (3) marks a major milestone: our first true flagship, delivering the very best of Nothing. We can't wait for our Indian users to experience it.' Apart from this, Nothing is also expanding its post-sales support in India. The company now runs five exclusive service centers in Bengaluru, Delhi, Mumbai, Hyderabad, and Chennai, plus 20 priority desks (with 10 more on the way) and over 330 authorized service centers nationwide. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo With these efforts, the company plans to improve customer experience and provide timely support across regions. Meanwhile, Nothing's retail footprint has grown from 2,000 stores at the start of last year to 10,000 at present, that can help the company to boost its postion in India's smartphone market.
